Steven H. Holtzman is a founder, Chair, President, and Chief Executive Officer. From early 1994 - 2001, Mr. Holtzman served as an early leader and the Chief Business Officer of Millennium Pharmaceuticals, a leading biopharmaceutical company. Prior to joining Millennium, from 1986-1994, Mr. Holtzman was a founder, the first employee, and Executive Vice President of DNX Corporation, the first commercial enterprise devoted to the development of agricultural, biomedical, and pharmaceutical applications of transgenic animal technology. Prior to DNX, in the early 1980's, Mr. Holtzman conceived of and was the founding Executive Director of the Ohio Edison Program, the nation's first state government program directed to achieving economic development through funding young technology-based ventures and university/industry collaborative research and development efforts. In the late 1970's, Mr. Holtzman was an instructor and tutor in moral philosophy and the philosophy of language at Corpus Christi College, Oxford University, U.K.

Mr. Holtzman co-founded and from 1995-2000 was the Co-Chair of the Biotechnology Industry Organization (BIO) Bioethics Committee. From 1996-2001, he served as a presidential appointee to the National Bioethics Advisory Commission, the principal advisory body to the President and Congress on ethical issues in the biomedical and life sciences. He is a member of the Board of Directors of Anadys Pharmaceuticals, Inc. and of BIO.  He is a Trustee of The Hastings Center for Bioethics and a Trustee of the Berklee College of Music. Mr. Holtzman received his B.A. in Philosophy from Michigan State University and his B.Phil. graduate degree in Philosophy from Oxford University, which he attended as a Rhodes Scholar.

Martin Babler is Chief Executive Officer of Talima Therapeutics, Inc., a privately-held drug delivery company, a position he has held since February 2008. Prior to joining Talima, from 2000 to 2006, Mr. Babler was Vice President of Immunology Sales and Marketing, and Director of Cardiovascular Marketing, at Genentech, Inc. Prior to joining Genentech, Mr. Babler held various roles of increasing responsibility in sales, sales management, marketing and business development with Eli Lilly and Company. Mr. Babler holds a degree in Pharmacy/Pharmacology from the ETH in Zurich, Switzerland and has attended the Executive Development Program at Kellogg Graduate School of Management.

Anthony B. Evnin, Ph.D., Chair of Infinity’s Nominating and Governance Committee, has served as Managing General Partner of Venrock Associates since 1980. and has been employed by Venrock Associates since 1974. Dr. Evnin also serves as a director of several private companies, as well as the following publicly traded biopharmaceutical companies: Icagen, Inc.; Memory Pharmaceuticals Corp.; Pharmos Corporation; Renovis, Inc.; Coley Pharmaceuticals, Inc.; and Sunesis Pharmaceuticals, Inc. Dr. Evnin received an A.B. in Chemistry from Princeton University and a Ph.D. in Chemistry from the Massachusetts Institute of Technology.

Harry F. Hixson, Jr., Ph.D. was Chairman of Discovery Partners International, Inc. prior to its merger with Infinity. Dr. Hixson is currently Chairman of BrainCells, Inc., a private biopharmaceutical company, and served as Chief Executive Officer from its founding until 2005. From 1998 - 2002, Dr. Hixson served as Chief Executive Officer of Elitra Pharmaceuticals, a private biopharmaceutical company, and as its Chairman from 1998 - 2003. Dr. Hixson was employed by Amgen Inc., a publicly traded biopharmaceutical company, from 1985 - 1991 and served as a Director and as the President and Chief Operating Officer. Dr. Hixson was employed by Abbott Laboratories, a publicly traded biopharmaceutical company, from 1974 - 1984 in various research and development and general management positions in the United States and Japan. Dr. Hixson is also Chairman of SEQUENOM, a publicly traded human genetics products and services company, and a director of Arena Pharmaceuticals, a publicly traded pharmaceutical company. Dr. Hixson received a B.S. in Chemical Engineering from Purdue University, an M.B.A. from The University of Chicago, and a Ph.D. in Physical Biochemistry from Purdue University. Dr. Hixson has also received an Honorary Doctor of Science degree from Purdue University.

Eric S. Lander, Ph.D., is a co-founder of Infinity. Dr. Lander has been a Professor and Associate Professor of Biology at the Massachusetts Institute of Technology since 1990 and a Professor of Systems Biology at Harvard Medical School since 2004. Dr. Lander has served as the founding Director of The Eli and Edythe L. Broad Institute, a biomedical research institute formed by MIT and Harvard University, since 2003 and as a member of the Whitehead Institute for Biomedical Research since 1989. From 1993 - 2003, Dr. Lander was the Director of the Whitehead/MIT Center for Genome Research. Dr. Lander received an A.B. in Mathematics from Princeton University and a D.Phil. in Mathematics from Oxford University, which he attended as a Rhodes Scholar.

Patrick Lee, Chair of Infinity’s Audit Committee, is a General Partner of Advent Venture Partners, a venture capital firm, where he has been employed since 1999. Prior to joining Advent Venture Partners, from 1989 - 1999, Mr. Lee held various positions with Rhone-Poulenc Rorer in the U.S., and Rhone-Poulenc in Paris, France, where he was most recently Group Vice President for Mergers and Acquisitions. Prior to that he had been with Baxter International and Booz Allen Hamilton. Mr. Lee received a B.A. in Biology from Vassar College and an M.B.A. from the Stanford Graduate School of Business.

Arnold J. Levine, Ph.D., Lead Research & Development Director, is a Professor at The Cancer Institute of New Jersey, Robert Wood Johnson School of Medicine and a Professor at the Institute for Advanced Study. From 1998 - 2002, Dr. Levine was President of Rockefeller University. Prior to joining Rockefeller University, Dr. Levine was the Harry C. Weiss Professor in the Life Sciences and Chairman of the Department of Molecular Biology at Princeton University from 1984 - 1996. Dr. Levine also serves as a Director of Theravance, Inc. and Applera Corporation, publicly traded life science companies. Dr. Levine received a B.A. in Biology from Harpur College, State University of New York at Binghamton and a Ph.D. in Microbiology from the University of Pennsylvania.

Frank Moss, Ph.D., is a co-founder of Infinity. Since 1998, Dr. Moss has been President of Strategic Software Ventures, a firm that nurtures enterprise software startup companies; since February 2006, Dr. Moss has served as Director of The Media Lab and Weisner Professor of Media Arts and Sciences at the Massachusetts Institute of Technology.From 1991 - 1996, Dr. Moss served as Chief Executive Officer and Chairman of Tivoli Systems, a private software company sold to IBM in 1996. Prior to joining Tivoli Systems, Dr. Moss held a variety of positions with Lotus Development, Stellar Computer, Apollo Computer, and IBM Research. Dr. Moss received a B.S. in Aerospace and Mechanical Sciences from Princeton University and an S.M. and Ph.D. in Aeronautics and Astronautics from the Massachusetts Institute of Technology.

Vicki L. Sato, Ph.D., Lead Outside Director and Chair of Infinity's Compensation Committee, is currently a professor at Harvard University. From 1992 - 2005, Dr. Sato held various positions with Vertex Pharmaceuticals, Inc., a publicly traded pharmaceutical company, most recently serving as President from 2000 - 2005. Prior to joining Vertex Pharmaceuticals, Inc., from 1984 - 1992, Dr. Sato held various positions with Biogen, Inc., a publicly traded biotechnology company, most recently serving as Vice President of Research and a member of the Scientific Advisory Board. Since 1993, Dr. Sato has served on the Board of Tutors, Department of Biochemistry and Molecular Biology at Harvard University, and also served as an Assistant Professor and Associate Professor in the Department of Biology at Harvard University from 1975 - 1983. Dr. Sato is a business advisor to Atlas Ventures, a venture capital firm, and other enterprises in the biotechnology and pharmaceutical industries. Dr. Sato serves as an overseer of the Isabella Stewart Gardner Museum and is a trustee of Jose Mateo’s Ballet Theatre. Dr. Sato serves as a director of Bristol-Myers Squibb Company and Alnylam Pharmaceuticals, Inc., publicly traded biopharmaceutical companies, Perkin-Elmer, Inc., a diversified company with businesses in the life and analytical sciences and optoelectronics, and Avila Therapeutics, a private biotechnology company. Dr. Sato received an A.B. in Biology from Radcliffe College and an M.A. and Ph.D. in Biology from Harvard University.

Ian F. Smith is Executive Vice President and Chief Financial Officer of Vertex Pharmaceuticals, Inc., a position he has held since February 2006. From November 2003 to February 2006, he was Vertex’s Senior Vice President and Chief Financial Officer, and from October 2001 to November 2003, he served as Vertex’s Vice President and Chief Financial Officer. Prior to joining Vertex, Mr. Smith served as a partner in the Life Science and Technology Practice Group of Ernst & Young LLP, an accounting firm, from 1999 to 2001. Mr. Smith initially joined Ernst & Young’s U.K. firm in 1987, and then joined its Boston office in 1995. Mr. Smith currently is a member of the Board of Directors of Acorda Therapeutics, Inc., Epix Pharmaceuticals, Inc. and TolerRx Inc., all publicly-traded biopharmaceutical companies. Mr. Smith holds a B.A. in accounting and finance from Manchester Metropolitan University, U.K., is a member of the American Institute of Certified Public Accountants and is a Chartered Accountant of England and Wales.

James B. Tananbaum, M.D., M.B.A., is a Managing Director of Prospect Venture Partners II, L.P. and Prospect Venture Partners III, L.P., venture partnerships he co-founded. From 1997 - 2000, Dr. Tananbaum served as Chief Executive Officer of Theravance, Inc., a publicly traded biopharmaceutical company. From 1993 - 1997, Dr. Tananbaum served as a partner of Sierra Ventures, a venture capital firm. Dr. Tananbaum also serves as a Director of Jazz Pharmaceuticals, a private biopharmaceutical company, and Novavax, Inc., a publicly traded biopharmaceutical company. Dr. Tananbaum received a B.S.E.E. from Yale University and an M.D. and M.B.A. from Harvard University.

Michael C. Venuti, Ph.D., Chair of Infinity's Research and Development Committee, is currently Chief Executive Officer of BioSeek, Inc. Dr. Venuti was formerly an Operating Partner at TPG Growth Biotech Ventures. Prior to TPG, he was the Acting Chief Executive Officer and Chief Scientific Officer of Discovery Partners International, Inc. prior to its merger with Infinity in September 2006. Dr. Venuti was a member of the Discovery Partners' Board of Directors since May 2003, and joined Discovery Partners as Chief Scientific Officer in April 2005. Prior to that, he was Senior Vice President of Pharmacogenomics, and was named Senior Vice President of Research and General Manager of Celera South San Francisco when Applera Corporation-Celera Genomics Group acquired Axys Pharmaceuticals in 2001. From 1994 through 2001, Dr. Venuti was Director of Medicinal Chemistry, and then Chief Technical Officer, for Axys Pharmaceuticals and its predecessor company, Arris Pharmaceutical Corporation, where he had overall responsibility for ten major pharma collaborations, and was responsible for the founding of a profitable combinatorial chemistry business later sold to Discovery Partners.

From 1988 - 1993, Dr. Venuti was Director of Bioorganic Chemistry at Genentech, Inc., leading the first group of medicinal chemists established in biotech to exploit the tools of recombinant DNA-based technology as applied to drug discovery. From 1980-1988, at Syntex Research, he led a medicinal chemistry group in the areas of enzyme inhibition and biochemical probes.

Dr. Venuti received an A.B. in Chemistry from Dartmouth College, a Ph.D. in Organic Chemsitry from the Massachusetts Institute of Technology, and completed postdoctoral training at the Institute of Organic Chemistry at Syntex Research, Palo Alto, California. Dr. Venuti has also held an appointment as Adjunct Professor of Chemistry in the Department of Pharmaceutical Chemistry at the University of California, San Francisco, since 1992.